Update shared on07 Aug 2025
Lantheus Holdings' valuation outlook remains stable as both the forward P/E ratio and revenue growth forecasts showed negligible changes, resulting in an unchanged analyst price target of $116.86.
What's in the News
- Lantheus completed its $200M share repurchase program, buying back 3.43% of shares; a new $400M repurchase authorization is in place through 2027, replacing the expired prior plan.
- The FDA accepted a New Drug Application for a new F-18 PSMA imaging agent formulation (by affiliate Aphelion), targeting expanded manufacturing capacity and access; review action date set for March 2026.
- Fiscal 2025 revenue guidance lowered to $1.475B–$1.51B from a prior $1.55B–$1.585B.
- Lantheus joined Pfizer and others in the FIBRE Consortium, aiming to advance imaging biomarkers for fibrotic diseases.
- New oncology radiodiagnostic data for PYLARIFY, the leading PSMA PET agent in the U.S., will be presented at the 2025 SNMMI Annual Meeting; safety information highlighted.
Valuation Changes
Summary of Valuation Changes for Lantheus Holdings
- The Consensus Analyst Price Target remained effectively unchanged, at $116.86.
- The Future P/E for Lantheus Holdings remained effectively unchanged, moving only marginally from 18.75x to 18.47x.
- The Consensus Revenue Growth forecasts for Lantheus Holdings remained effectively unchanged, at 9.0% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.